Kalaris Therapeutics (KLRS) Competitors $4.78 +0.25 (+5.52%) As of 02:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsOwnershipSEC FilingsShort InterestTrendsBuy This Stock KLRS vs. LFCR, ALEC, MREO, NGNE, ANNX, LXEO, ACB, TNXP, DBVT, and CADLShould you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include Lifecore Biomedical (LFCR), Alector (ALEC), Mereo BioPharma Group (MREO), Neurogene (NGNE), Annexon (ANNX), Lexeo Therapeutics (LXEO), Aurora Cannabis (ACB), Tonix Pharmaceuticals (TNXP), DBV Technologies (DBVT), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. Kalaris Therapeutics vs. Its Competitors Lifecore Biomedical Alector Mereo BioPharma Group Neurogene Annexon Lexeo Therapeutics Aurora Cannabis Tonix Pharmaceuticals DBV Technologies Candel Therapeutics Kalaris Therapeutics (NASDAQ:KLRS) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership. Does the media favor KLRS or LFCR? In the previous week, Lifecore Biomedical had 2 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 3 mentions for Lifecore Biomedical and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.89 beat Lifecore Biomedical's score of 0.88 indicating that Kalaris Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Kalaris Therapeutics Very Positive Lifecore Biomedical Positive Which has more risk and volatility, KLRS or LFCR? Kalaris Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Which has better valuation and earnings, KLRS or LFCR? Lifecore Biomedical has higher revenue and earnings than Kalaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalaris TherapeuticsN/AN/A-$58.77MN/AN/ALifecore Biomedical$128.87M2.02-$38.72M-$1.31-5.30 Do insiders & institutionals have more ownership in KLRS or LFCR? 66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 75.0% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 32.0% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer KLRS or LFCR? Kalaris Therapeutics currently has a consensus price target of $3.00, indicating a potential downside of 37.24%. Lifecore Biomedical has a consensus price target of $8.00, indicating a potential upside of 15.27%. Given Lifecore Biomedical's higher possible upside, analysts clearly believe Lifecore Biomedical is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is KLRS or LFCR more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -31.70%. Kalaris Therapeutics' return on equity of -81.02% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Kalaris TherapeuticsN/A -81.02% -65.15% Lifecore Biomedical -31.70%-846.51%-13.03% SummaryLifecore Biomedical beats Kalaris Therapeutics on 8 of the 14 factors compared between the two stocks. Get Kalaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.40M$3.07B$5.65B$10.26BDividend YieldN/A2.36%5.68%4.61%P/E RatioN/A20.6875.7026.05Price / SalesN/A397.57514.05168.79Price / CashN/A45.9137.5661.52Price / Book0.219.6212.876.29Net Income-$58.77M-$52.73M$3.29B$270.94M7 Day Performance8.88%0.59%-0.33%-0.30%1 Month Performance90.44%6.27%3.77%6.20%1 Year PerformanceN/A18.55%68.18%28.32% Kalaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSKalaris Therapeutics1.9764 of 5 stars$4.78+5.5%$3.00-37.2%N/A$89.40MN/A0.00110Positive NewsLFCRLifecore Biomedical1.3471 of 5 stars$7.52-3.2%$8.00+6.4%+41.3%$290.66M$128.87M-5.74690ALECAlector3.9029 of 5 stars$2.75-4.2%$4.17+51.5%-39.2%$290.48M$81.13M-2.37270Positive NewsAnalyst ForecastHigh Trading VolumeMREOMereo BioPharma Group2.1748 of 5 stars$1.85+1.6%$7.40+300.0%-55.6%$289.38M$500K-26.4340Positive NewsNGNENeurogene1.68 of 5 stars$19.00-5.4%$46.17+143.0%-57.6%$286.58M$930K-4.4190Positive NewsANNXAnnexon2.2095 of 5 stars$2.42-5.1%$12.50+416.5%-55.2%$280.21MN/A-1.8860Positive NewsHigh Trading VolumeLXEOLexeo Therapeutics2.5441 of 5 stars$5.18flat$15.33+196.0%-26.0%$279.73MN/A-1.5958News CoverageHigh Trading VolumeACBAurora Cannabis0.413 of 5 stars$4.87-1.2%N/A-9.8%$278.32M$357.88M-25.631,130TNXPTonix Pharmaceuticals3.3416 of 5 stars$28.61-8.3%$70.00+144.7%+90.0%$273.58M$10.09M-0.7250Analyst RevisionDBVTDBV Technologies2.4428 of 5 stars$9.87-0.8%$14.75+49.4%+151.2%$272.58M$4.15M-2.0780CADLCandel Therapeutics2.618 of 5 stars$4.79-2.4%$20.00+317.5%-22.8%$269.81M$120K-6.9460Positive News Related Companies and Tools Related Companies LFCR Competitors ALEC Competitors MREO Competitors NGNE Competitors ANNX Competitors LXEO Competitors ACB Competitors TNXP Competitors DBVT Competitors CADL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
